Fig 1. The Rh-α₄β₇-VRC01 combination significantly delays SHIV_AD8-EO acquisition.

(A) Schematic of the study procedures (B-C) The concentrations of VRC01 (B) and Rh-α₄β₇ (C) were measured in plasma for the first 8 weeks after initiation of treatment. VRC01 levels were below the protective concentration in GH63 and KT57 (orange and green in B, respectively). BL: right before the first infusion with VRC01 and Rh-α₄β₇ Solid colored line (red for VRC01 and blue for Rh-α₄β₇) represent the mean of all macaques. (D) Log viral RNA (copies/ml) in plasma are shown from the time of the first challenge (week 0). (E) Kaplan-Meier curves generated with time to first viral detection in plasma are shown. Curves were compared with the Log-rank test (* p-value = 0.016; Gehan-Breslow-Wilcoxon test p = 0.015) α<0.05 (Bonferroni corrected for multiple comparisons at α<0.017 was considered significant). (F-G) Mean ± SEM of the plasma viral loads (F) and CD4⁺ T cell counts (G) are shown.